Identification

Name
Iloprost
Accession Number
DB01088  (APRD01027)
Type
Small Molecule
Groups
Approved, Investigational
Description

Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It is used to treat pulmonary arterial hypertension (PAH).

Structure
Thumb
Synonyms
Not Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
VentavisSolution.02 mg/mLRespiratory (inhalation)Actelion2009-08-24Not applicableUs
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution20 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution10 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
VentavisSolution.01 mg/mLRespiratory (inhalation)Actelion2005-05-07Not applicableUs
VentavisSolution20 μg/mlRespiratory (inhalation)Bayer Schering Pharma Ag2003-09-16Not applicableEu
Categories
UNII
JED5K35YGL
CAS number
78919-13-8
Weight
Average: 360.494
Monoisotopic: 360.23005951
Chemical Formula
C22H32O4
InChI Key
HIFJCPQKFCZDDL-ACWOEMLNSA-N
InChI
InChI=1S/C22H32O4/c1-3-4-7-15(2)20(23)11-10-18-19-13-16(8-5-6-9-22(25)26)12-17(19)14-21(18)24/h8,10-11,15,17-21,23-24H,5-7,9,12-14H2,1-2H3,(H,25,26)/b11-10+,16-8+/t15?,17-,18+,19-,20+,21+/m0/s1
IUPAC Name
5-[(2E,3aS,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-octahydropentalen-2-ylidene]pentanoic acid
SMILES
[H][[email protected]]12C[[email protected]@H](O)[[email protected]](\C=C\[[email protected]@H](O)C(C)CC#CC)[[email protected]@]1([H])C\C(C2)=C\CCCC(O)=O

Pharmacology

Indication

Used for the treatment of pulmonary arterial hypertension.

Structured Indications
Pharmacodynamics

Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the relevance of this effect to the treatment of pulmonary hypertension is unknown. The two diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S isomer substantially more potent than the 4R isomer.

Mechanism of action

Iloprost is a second generation structural analog of prostacyclin (PGI) with about ten-fold greater potency than the first generation stable analogs, such as carbaprostacyclin. Iloprost binds with equal affinity to human prostacyclin (Prostanoid IP) and prostaglandin EP1 receptors. Iloprost constricts the ilium and fundus circular smooth muscle as strongly as prostaglandin E2 (PGE2) itself. Iloprost inhibits the ADP, thrombin, and collagen-induced aggregation of human platelets. In whole animals, iloprost acts as a vasodilator, hypotensive, antidiuretic, and prolongs bleeding time. All of these properties help to antagonize the pathological changes that take place in the small pulmonary arteries of patients with pulmonary hypertension.

TargetActionsOrganism
AProstacyclin receptor
agonist
Human
AProstaglandin E2 receptor EP1 subtype
agonist
Human
UcAMP-specific 3',5'-cyclic phosphodiesterase 4A
inducer
Human
UcAMP-specific 3',5'-cyclic phosphodiesterase 4B
inducer
Human
UcAMP-specific 3',5'-cyclic phosphodiesterase 4C
inducer
Human
UcAMP-specific 3',5'-cyclic phosphodiesterase 4D
inducer
Human
UTissue-type plasminogen activator
other/unknown
Human
UProstaglandin D2 receptor 2
agonist
Human
Absorption

Rapidly absorbed with bioavailability of 63%

Volume of distribution
  • 0.7 to 0.8 L/kg
Protein binding

60%

Metabolism

Primarily hepatic. Iloprost is metabolized principally via beta-oxidation of the carboxyl side chain.

Route of elimination
Not Available
Half life

20-30 minutes

Clearance
  • 20 mL/min/kg [Normal subjects]
Toxicity

Overdoses can lead to hypotension, headache, flushing, nausea, vomiting, and diarrhea.

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabIloprost may increase the anticoagulant activities of Abciximab.Approved
AceclofenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aceclofenac.Approved, Investigational
AcemetacinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolIloprost may increase the anticoagulant activities of Acenocoumarol.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Iloprost is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Adapalene.Approved
AlclofenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Alclofenac.Approved, Withdrawn
AlminoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Alminoprofen.Experimental
AloxiprinThe risk or severity of adverse effects can be increased when Iloprost is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the anticoagulant activities of Iloprost.Approved, Investigational
AlteplaseIloprost may increase the anticoagulant activities of Alteplase.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Iloprost.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Iloprost is combined with Aminosalicylic Acid.Approved
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Iloprost.Approved, Investigational
AmobarbitalAmobarbital may increase the hypotensive activities of Iloprost.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Iloprost.Approved, Investigational
AnagrelideAnagrelide may increase the anticoagulant activities of Iloprost.Approved
AncrodIloprost may increase the anticoagulant activities of Ancrod.Investigational
AndrographolideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Andrographolide.Investigational
AnisodamineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Anisodamine.Investigational
AnistreplaseIloprost may increase the anticoagulant activities of Anistreplase.Approved
AntipyrineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Antipyrine.Approved
Antithrombin III humanIloprost may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Iloprost is combined with Apixaban.Approved
ApocyninThe therapeutic efficacy of Iloprost can be decreased when used in combination with Apocynin.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Iloprost.Approved, Investigational
ApremilastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Apremilast.Approved, Investigational
AprotininThe therapeutic efficacy of Iloprost can be decreased when used in combination with Aprotinin.Approved, Withdrawn
ArdeparinIloprost may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanIloprost may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Iloprost.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Iloprost.Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Iloprost.Approved, Investigational
AstaxanthinIloprost may increase the anticoagulant activities of Astaxanthin.Investigational
AzapropazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azapropazone.Withdrawn
AzelastineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Azelastine.Approved
BalsalazideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Balsalazide.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Iloprost.Experimental
BarbitalBarbital may increase the hypotensive activities of Iloprost.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Iloprost.Approved
BatroxobinIloprost may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminIloprost may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinIloprost may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BendazacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bendazac.Experimental
BenorilateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Benorilate.Experimental
BenoxaprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Benoxaprofen.Withdrawn
BenzydamineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Benzydamine.Approved
BeraprostIloprost may increase the anticoagulant activities of Beraprost.Investigational
BevoniumThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bevonium.Experimental
BivalirudinIloprost may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BortezomibThe risk or severity of adverse effects can be increased when Bortezomib is combined with Iloprost.Approved, Investigational
BrinaseIloprost may increase the anticoagulant activities of Brinase.Experimental
BromfenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bromfenac.Approved
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Iloprost.Approved, Investigational
BucillamineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bucillamine.Investigational
BufexamacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bufexamac.Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Iloprost.Experimental
BumadizoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Bumadizone.Experimental
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Iloprost.Approved, Investigational
ButylphthalideButylphthalide may increase the anticoagulant activities of Iloprost.Investigational
CangrelorIloprost may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabIloprost may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Iloprost is combined with Carbaspirin calcium.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Iloprost.Approved
CarprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Carprofen.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Castanospermine.Experimental
CelecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Celecoxib.Approved, Investigational
CertoparinIloprost may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Chloroquine.Approved, Vet Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Iloprost.Approved, Vet Approved
Choline magnesium trisalicylateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Choline magnesium trisalicylate.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Iloprost.Approved, Investigational
CilostazolIloprost may increase the anticoagulant activities of Cilostazol.Approved
Citric AcidIloprost may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Iloprost.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Clomipramine is combined with Iloprost.Approved, Vet Approved
ClonixinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Clonixin.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Iloprost.Approved
CloricromenIloprost may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneIloprost may increase the anticoagulant activities of Clorindione.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Iloprost.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Iloprost is combined with Collagenase clostridium histolyticum.Approved, Investigational
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Iloprost.Approved, Investigational
CurcuminThe therapeutic efficacy of Iloprost can be decreased when used in combination with Curcumin.Investigational
Dabigatran etexilateIloprost may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinIloprost may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidIloprost may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanIloprost may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Iloprost.Approved, Investigational
DefibrotideIloprost may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Iloprost is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Iloprost is combined with Dersalazine.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Iloprost.Approved
DesirudinIloprost may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseIloprost may increase the anticoagulant activities of Desmoteplase.Investigational
DextranIloprost may increase the anticoagulant activities of Dextran.Approved, Vet Approved
Dextran 40Iloprost may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Iloprost may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Iloprost may increase the anticoagulant activities of Dextran 75.Approved
DiclofenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Diclofenac.Approved, Vet Approved
DicoumarolIloprost may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Difenpiramide.Experimental
DiflunisalThe risk or severity of adverse effects can be increased when Iloprost is combined with Diflunisal.Approved
DiphenadioneIloprost may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Iloprost.Approved
DitazoleIloprost may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaIloprost may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
DroxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Droxicam.Withdrawn
DuloxetineIloprost may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Duvelisib.Investigational
E-6201The therapeutic efficacy of Iloprost can be decreased when used in combination with E-6201.Investigational
Edetic AcidIloprost may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanIloprost may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinIloprost may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the anticoagulant activities of Iloprost.Approved, Investigational
EpirizoleThe therapeutic efficacy of Iloprost can be decreased when used in combination with Epirizole.Approved
EplivanserinIloprost may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineIloprost may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Iloprost.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Iloprost.Approved, Investigational
EtanerceptThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etanercept.Approved, Investigational
EthenzamideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ethenzamide.Experimental
Ethyl biscoumacetateIloprost may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etofenamate.Approved, Investigational
EtoricoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Etoricoxib.Approved, Investigational
Evening primrose oilThe therapeutic efficacy of Iloprost can be decreased when used in combination with Evening primrose oil.Approved, Investigational
ExisulindThe therapeutic efficacy of Iloprost can be decreased when used in combination with Exisulind.Investigational
FelbinacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Felbinac.Experimental
FenbufenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenbufen.Approved
FenoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fenoprofen.Approved
FentiazacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Fentiazac.Experimental
FeprazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Feprazone.Experimental
Ferulic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ferulic acid.Experimental
FibrinolysinIloprost may increase the anticoagulant activities of Fibrinolysin.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Iloprost.Approved, Investigational
FloctafenineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Floctafenine.Approved, Withdrawn
FluindioneIloprost may increase the anticoagulant activities of Fluindione.Investigational
FlunixinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flunixin.Vet Approved
FlunoxaprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flunoxaprofen.Experimental
FlurbiprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Flurbiprofen.Approved, Investigational
FondaparinuxIloprost may increase the anticoagulant activities of Fondaparinux.Investigational
Fondaparinux sodiumIloprost may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateIloprost may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Iloprost.Approved
GuacetisalThe risk or severity of adverse effects can be increased when Iloprost is combined with Guacetisal.Experimental
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Iloprost.Approved, Vet Approved
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Iloprost is combined with Hemoglobin crosfumaril.Experimental
HeparinIloprost may increase the anticoagulant activities of Heparin.Approved, Investigational
HexobarbitalHexobarbital may increase the hypotensive activities of Iloprost.Approved
HigenamineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Higenamine.Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Iloprost.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Iloprost is combined with Ibritumomab tiuxetan.Approved
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Iloprost.Approved
IbudilastIbudilast may increase the anticoagulant activities of Iloprost.Approved, Investigational
IbuprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ibuprofen.Approved
IbuproxamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ibuproxam.Withdrawn
IcatibantThe therapeutic efficacy of Iloprost can be decreased when used in combination with Icatibant.Approved
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Iloprost.Approved, Nutraceutical
IdraparinuxIloprost may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Iloprost.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Iloprost.Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Iloprost is combined with Imidapril.Investigational
Imidazole salicylateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Imidazole salicylate.Experimental
ImipramineThe risk or severity of adverse effects can be increased when Iloprost is combined with Imipramine.Approved
IndobufenIloprost may increase the anticoagulant activities of Indobufen.Investigational
IndomethacinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indomethacin.Approved, Investigational
IndoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Indoprofen.Withdrawn
IsocarboxazidThe risk or severity of adverse effects can be increased when Iloprost is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Iloprost is combined with Isoflurane.Approved, Vet Approved
IsoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Isoxicam.Withdrawn
KebuzoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Kebuzone.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Iloprost.Investigational
KetoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketoprofen.Approved, Vet Approved
KetorolacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ketorolac.Approved
LacidipineIloprost may increase the hypotensive activities of Lacidipine.Approved, Investigational
LeflunomideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Leflunomide.Approved, Investigational
LepirudinIloprost may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanIloprost may increase the anticoagulant activities of Letaxaban.Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Iloprost is combined with Levobupivacaine.Approved, Investigational
LevodopaIloprost may increase the orthostatic hypotensive activities of Levodopa.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Iloprost is combined with Levosimendan.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Iloprost.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Iloprost.Experimental
LisofyllineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lisofylline.Investigational
LonazolacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lonazolac.Experimental
LornoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lornoxicam.Approved, Investigational
LoxoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Loxoprofen.Approved, Investigational
LumiracoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Lumiracoxib.Approved, Investigational
Magnesium salicylateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Magnesium salicylate.Approved
MasoprocolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Masoprocol.Approved, Investigational
Meclofenamic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meclofenamic acid.Approved, Vet Approved
Mefenamic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mefenamic acid.Approved
MelagatranIloprost may increase the anticoagulant activities of Melagatran.Experimental
MeloxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Meloxicam.Approved, Vet Approved
MesalazineThe risk or severity of adverse effects can be increased when Iloprost is combined with Mesalazine.Approved
MetamizoleThe therapeutic efficacy of Iloprost can be decreased when used in combination with Metamizole.Investigational, Withdrawn
MethohexitalMethohexital may increase the hypotensive activities of Iloprost.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Iloprost is combined with Methyl salicylate.Approved, Vet Approved
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Iloprost.Approved
MilrinoneMilrinone may increase the anticoagulant activities of Iloprost.Approved
MizoribineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mizoribine.Investigational
MofebutazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mofebutazone.Experimental
MorphineThe risk or severity of adverse effects can be increased when Iloprost is combined with Morphine.Approved, Investigational
Mycophenolate mofetilThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolate mofetil.Approved, Investigational
Mycophenolic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Mycophenolic acid.Approved
NabiloneThe risk or severity of adverse effects can be increased when Iloprost is combined with Nabilone.Approved, Investigational
NabumetoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nabumetone.Approved
NadroparinIloprost may increase the anticoagulant activities of Nadroparin.Approved
NafamostatThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nafamostat.Approved, Investigational
NaftifineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naftifine.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Iloprost.Investigational
NaproxenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Naproxen.Approved, Vet Approved
NepafenacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nepafenac.Approved
NicorandilNicorandil may increase the hypotensive activities of Iloprost.Approved, Investigational
NifenazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nifenazone.Experimental
Niflumic AcidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Niflumic Acid.Approved
NimesulideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Nimesulide.Approved, Investigational, Withdrawn
Nitric OxideThe risk or severity of adverse effects can be increased when Iloprost is combined with Nitric Oxide.Approved
NitroaspirinThe risk or severity of adverse effects can be increased when Iloprost is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Iloprost is combined with Obinutuzumab.Approved
OlopatadineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olopatadine.Approved
OlsalazineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Iloprost.Approved, Nutraceutical
OrgoteinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Orgotein.Vet Approved
OtamixabanIloprost may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxaprozin.Approved
OxyphenbutazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Oxyphenbutazone.Approved, Withdrawn
OzagrelIloprost may increase the anticoagulant activities of Ozagrel.Investigational
PaclitaxelThe risk or severity of adverse effects can be increased when Iloprost is combined with Paclitaxel.Approved, Vet Approved
ParecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Parecoxib.Approved
ParnaparinIloprost may increase the anticoagulant activities of Parnaparin.Approved, Investigational
ParthenolideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Parthenolide.Investigational
Pentaerythritol TetranitrateIloprost may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Iloprost.Approved, Vet Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Iloprost.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Iloprost.Approved, Investigational
PhenelzineThe risk or severity of adverse effects can be increased when Iloprost is combined with Phenelzine.Approved
PhenindioneIloprost may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenobarbitalPhenobarbital may increase the hypotensive activities of Iloprost.Approved
PhenprocoumonIloprost may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Phenylbutazone.Approved, Vet Approved
PicotamideIloprost may increase the anticoagulant activities of Picotamide.Experimental
PimecrolimusThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pimecrolimus.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Iloprost is combined with Pipamperone.Approved, Investigational
PirfenidoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pirfenidone.Approved, Investigational
PiroxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Piroxicam.Approved, Investigational
PirprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pirprofen.Experimental
PramipexoleThe risk or severity of adverse effects can be increased when Iloprost is combined with Pramipexole.Approved, Investigational
PranoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Pranoprofen.Experimental, Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Iloprost.Approved
PrimidonePrimidone may increase the hypotensive activities of Iloprost.Approved, Vet Approved
ProglumetacinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Proglumetacin.Experimental
PropacetamolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Propacetamol.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Iloprost is combined with Propofol.Approved, Investigational, Vet Approved
PropyphenazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Propyphenazone.Experimental
ProquazoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Proquazone.Experimental
Protein CIloprost may increase the anticoagulant activities of Protein C.Approved
Protein S humanIloprost may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeIloprost may increase the anticoagulant activities of Protocatechualdehyde.Approved
PTC299The therapeutic efficacy of Iloprost can be decreased when used in combination with PTC299.Investigational
RamatrobanRamatroban may increase the anticoagulant activities of Iloprost.Investigational
RasagilineThe risk or severity of adverse effects can be increased when Iloprost is combined with Rasagiline.Approved
RelcovaptanRelcovaptan may increase the anticoagulant activities of Iloprost.Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Iloprost is combined with Remifentanil.Approved
ResveratrolThe therapeutic efficacy of Iloprost can be decreased when used in combination with Resveratrol.Approved, Experimental, Investigational
ReteplaseIloprost may increase the anticoagulant activities of Reteplase.Approved
ReviparinIloprost may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Iloprost.Approved
RisperidoneIloprost may increase the hypotensive activities of Risperidone.Approved, Investigational
RivaroxabanIloprost may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Rofecoxib.Investigational, Withdrawn
RopiniroleThe risk or severity of adverse effects can be increased when Iloprost is combined with Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Iloprost is combined with Ropivacaine.Approved
RosiglitazoneIloprost may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
RotigotineThe risk or severity of adverse effects can be increased when Iloprost is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Iloprost is combined with Sacubitril.Approved
SalicylamideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Iloprost is combined with Salicylic acid.Approved, Vet Approved
SalsalateThe therapeutic efficacy of Iloprost can be decreased when used in combination with Salsalate.Approved
SarpogrelateIloprost may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseIloprost may increase the anticoagulant activities of Saruplase.Experimental
SecobarbitalSecobarbital may increase the hypotensive activities of Iloprost.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Iloprost is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagIloprost may increase the anticoagulant activities of Selexipag.Approved
SemapimodThe therapeutic efficacy of Iloprost can be decreased when used in combination with Semapimod.Investigational
SeratrodastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Seratrodast.Approved
SerrapeptaseThe therapeutic efficacy of Iloprost can be decreased when used in combination with Serrapeptase.Investigational
SevofluraneThe risk or severity of adverse effects can be increased when Iloprost is combined with Sevoflurane.Approved, Vet Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Iloprost is combined with Sodium Nitrite.Approved
SRT501The therapeutic efficacy of Iloprost can be decreased when used in combination with SRT501.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Iloprost is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Iloprost is combined with Sufentanil.Approved, Investigational
SulfasalazineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulfasalazine.Approved
SulindacThe therapeutic efficacy of Iloprost can be decreased when used in combination with Sulindac.Approved
SulodexideIloprost may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SuprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Suprofen.Approved, Withdrawn
SuxibuzoneThe therapeutic efficacy of Iloprost can be decreased when used in combination with Suxibuzone.Experimental
TamsulosinThe risk or severity of adverse effects can be increased when Iloprost is combined with Tamsulosin.Approved, Investigational
TarenflurbilThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tarenflurbil.Investigational
TenecteplaseIloprost may increase the anticoagulant activities of Tenecteplase.Approved
TenidapThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tenidap.Experimental
TenoxicamThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tenoxicam.Approved
TepoxalinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tepoxalin.Vet Approved
TeriflunomideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Teriflunomide.Approved
TesmilifeneTesmilifene may increase the anticoagulant activities of Iloprost.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Iloprost is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the hypotensive activities of Iloprost.Approved, Vet Approved
ThiopentalThiopental may increase the hypotensive activities of Iloprost.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Iloprost is combined with Thioridazine.Approved, Withdrawn
Tiaprofenic acidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tiaprofenic acid.Approved
TicagrelorIloprost may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Iloprost.Approved
TinoridineThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tinoridine.Investigational
TinzaparinIloprost may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolIloprost may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Iloprost.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Iloprost.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Iloprost is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolfenamic Acid.Approved
TolmetinThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tolmetin.Approved
TositumomabThe risk or severity of adverse effects can be increased when Iloprost is combined with Tositumomab.Approved, Investigational
TranilastThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Iloprost is combined with Tranylcypromine.Approved
TrapidilTrapidil may increase the anticoagulant activities of Iloprost.Approved
TreprostinilIloprost may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Iloprost is combined with Tretinoin.Approved, Investigational, Nutraceutical
TribenosideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Tribenoside.Experimental
TriflusalIloprost may increase the anticoagulant activities of Triflusal.Approved, Investigational
TriptolideThe therapeutic efficacy of Iloprost can be decreased when used in combination with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Iloprost is combined with Trolamine salicylate.Approved
TroxerutinIloprost may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseIloprost may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValdecoxibThe therapeutic efficacy of Iloprost can be decreased when used in combination with Valdecoxib.Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Iloprost.Approved, Nutraceutical, Vet Approved
VorapaxarVorapaxar may increase the anticoagulant activities of Iloprost.Approved
WarfarinIloprost may increase the anticoagulant activities of Warfarin.Approved
XimelagatranIloprost may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zaltoprofen.Approved, Investigational
ZileutonThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zileuton.Approved, Investigational, Withdrawn
ZomepiracThe therapeutic efficacy of Iloprost can be decreased when used in combination with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
5311181
PubChem Substance
46507818
ChemSpider
4470703
BindingDB
23954
ChEBI
63916
ChEMBL
CHEMBL494
Therapeutic Targets Database
DAP000273
PharmGKB
PA164746843
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Iloprost
ATC Codes
B01AC11 — Iloprost
FDA label
Download (244 KB)
MSDS
Download (67.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedNot AvailableAsthma Bronchial1
1CompletedTreatmentAcute Lung Injury (ALI) / Acute Respiratory Distress Syndrome (ARDS) / Pulmonary Hypertension (PH)1
1RecruitingPreventionCytologic Atypia / Former Smoker / Lung, Carcinoma / Mild Dysplasia / Precancerous Conditions1
1Unknown StatusBasic ScienceHypoxic Pulmonary Vasoconstriction1
1WithdrawnBasic ScienceHypoxic Pulmonary Vasoconstriction1
1, 2CompletedTreatmentHealthy Volunteers1
1, 2CompletedTreatmentMyocardial Infarction (MI)1
1, 2WithdrawnTreatmentAcute Respiratory Distress Syndrome (ARDS) / Defect, Congenital Heart / Neonatal Hypoxic Respiratory Failure / Persistent Pulmonary Hypertension of Newborn (PPHN) / Pulmonary Hypertension (PH)1
2CompletedBasic ScienceChronic Obstructive Pulmonary Disease (COPD)1
2CompletedPreventionLung Cancers / Precancerous Conditions1
2CompletedTreatmentAyerza Syndrome / Pulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)1
2CompletedTreatmentCardiac Arrest1
2CompletedTreatmentPulmonary Fibrosis / Pulmonary Hypertension (PH)1
2CompletedTreatmentPulmonary Hypertension (PH)2
2RecruitingTreatmentResidual Pulmonary Hypertension1
2TerminatedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
2TerminatedTreatmentPulmonary Hypertension (PH)1
2TerminatedTreatmentSclerosis, Progressive Systemic1
2Unknown StatusTreatmentShock, Septic1
2WithdrawnTreatmentPulmonary Arterial Hypertension (PAH)1
2, 3CompletedPreventionAngioplasty, Transluminal, Percutaneous Coronary / Coronary Angiography / Renal Insufficiency,Chronic1
3CompletedTreatmentPulmonary Arterial Hypertension (PAH)2
3CompletedTreatmentPulmonary Hypertension (PH)4
3CompletedTreatmentRaynaud's Disease / Sclerosis, Progressive Systemic1
3Not Yet RecruitingTreatmentRespiratory Distress Syndrome, Adult1
3TerminatedTreatmentPulmonary Arterial Hypertension (PAH)1
3TerminatedTreatmentPulmonary Hypertension (PH)1
3Unknown StatusTreatmentPulmonary Arterial Hypertension (PAH)1
4CompletedNot AvailableHypertension,Essential1
4CompletedTreatmentPeripheral Arterial Disease (PAD)1
4CompletedTreatmentPulmonary Arterial Hypertension (PAH) / Sarcoidosis1
4Not Yet RecruitingDiagnosticPulmonary Hypertension (PH)1
4RecruitingTreatmentPulmonary Arterial Hypertension (PAH)1
4TerminatedTreatmentPulmonary Hypertension (PH)2
Not AvailableActive Not RecruitingNot AvailablePulmonary Hypertension (PH)2
Not AvailableCompletedNot AvailablePeripheral Arterial Disease (PAD)1
Not AvailableCompletedNot AvailablePulmonary Arterial Hypertension (PAH)3
Not AvailableCompletedNot AvailablePulmonary Hypertension (PH)4
Not AvailableCompletedTreatmentChronic Obstructive Pulmonary Disease (COPD) / Pulmonary Hypertension (PH)1
Not AvailableCompletedTreatmentInsulin Sensitivity/Resistance / Type 2 Diabetes Mellitus1
Not AvailableNot Yet RecruitingNot AvailablePulmonary Hypertension (PH)1
Not AvailableRecruitingNot AvailablePulmonary Hypertension (PH)1
Not AvailableRecruitingBasic SciencePulmonary Arterial Hypertension (PAH) / Pulmonary Hypertension (PH)1
Not AvailableRecruitingTreatmentLung Cancers1
Not AvailableTerminatedNot AvailablePulmonary Arterial Hypertension (PAH)1
Not AvailableTerminatedTreatmentCongenital Heart Disease (CHD) / Eisenmenger's Syndrome / Pulmonary Arterial Hypertension (PAH)1
Not AvailableUnknown StatusNot AvailablePregnancy1
Not AvailableWithdrawnTreatmentPersistent Pulmonary Hypertension / Respiratory Distress Syndrome (RDS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
SolutionRespiratory (inhalation).01 mg/mL
SolutionRespiratory (inhalation).02 mg/mL
SolutionRespiratory (inhalation)10 μg/ml
SolutionRespiratory (inhalation)20 μg/ml
Prices
Unit descriptionCostUnit
Ventavis 10 mcg/1 ml solution74.4USD ml
Ventavis 20 mcg/1 ml solution74.4USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
water solubilityVery slightly solubleNot Available
logP4.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00874 mg/mLALOGPS
logP4.22ALOGPS
logP3.56ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)4.66ChemAxon
pKa (Strongest Basic)-0.87ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area77.76 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity105.18 m3·mol-1ChemAxon
Polarizability42.68 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9543
Blood Brain Barrier+0.5506
Caco-2 permeable+0.5
P-glycoprotein substrateSubstrate0.7459
P-glycoprotein inhibitor INon-inhibitor0.6507
P-glycoprotein inhibitor IINon-inhibitor0.8227
Renal organic cation transporterNon-inhibitor0.8698
CYP450 2C9 substrateNon-substrate0.8526
CYP450 2D6 substrateNon-substrate0.8946
CYP450 3A4 substrateSubstrate0.6553
CYP450 1A2 substrateNon-inhibitor0.5515
CYP450 2C9 inhibitorNon-inhibitor0.7963
CYP450 2D6 inhibitorNon-inhibitor0.8072
CYP450 2C19 inhibitorNon-inhibitor0.719
CYP450 3A4 inhibitorInhibitor0.5377
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7556
Ames testNon AMES toxic0.7104
CarcinogenicityNon-carcinogens0.9587
BiodegradationNot ready biodegradable0.6052
Rat acute toxicity2.7260 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9288
hERG inhibition (predictor II)Non-inhibitor0.6964
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as prostaglandins and related compounds. These are unsaturated carboxylic acids consisting of a 20 carbon skeleton that also contains a five member ring, and are based upon the fatty acid arachidonic acid.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Eicosanoids
Direct Parent
Prostaglandins and related compounds
Alternative Parents
Bicyclic monoterpenoids / Medium-chain hydroxy acids and derivatives / Fatty alcohols / Medium-chain fatty acids / Hydroxy fatty acids / Branched fatty acids / Secondary alcohols / Cyclic alcohols and derivatives / Monocarboxylic acids and derivatives / Carboxylic acids
show 3 more
Substituents
Prostaglandin skeleton / Bicyclic monoterpenoid / Monoterpenoid / Fatty alcohol / Medium-chain hydroxy acid / Medium-chain fatty acid / Branched fatty acid / Hydroxy fatty acid / Cyclic alcohol / Secondary alcohol
show 10 more
Molecular Framework
Aliphatic homopolycyclic compounds
External Descriptors
monocarboxylic acid, secondary alcohol, carbobicyclic compound (CHEBI:63916)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Guanyl-nucleotide exchange factor activity
Specific Function
Receptor for prostacyclin (prostaglandin I2 or PGI2). The activity of this receptor is mediated by G(s) proteins which activate adenylate cyclase.
Gene Name
PTGIR
Uniprot ID
P43119
Uniprot Name
Prostacyclin receptor
Molecular Weight
40955.485 Da
References
  1. Takamatsu H, Tsukada H, Watanabe Y, Cui Y, Kataoka Y, Hosoya T, Suzuki M, Watanabe Y: Specific ligand for a central type prostacyclin receptor attenuates neuronal damage in a rat model of focal cerebral ischemia. Brain Res. 2002 Jan 25;925(2):176-82. [PubMed:11792366]
  2. Crutchley DJ, Solomon DE, Conanan LB: Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism. Arterioscler Thromb. 1992 Jun;12(6):664-70. [PubMed:1375507]
  3. Schermuly RT, Pullamsetti SS, Breitenbach SC, Weissmann N, Ghofrani HA, Grimminger F, Nilius SM, Schror K, Kirchrath JM, Seeger W, Rose F: Iloprost-induced desensitization of the prostacyclin receptor in isolated rabbit lungs. Respir Res. 2007 Jan 26;8:4. [PubMed:17257398]
  4. Idzko M, Hammad H, van Nimwegen M, Kool M, Vos N, Hoogsteden HC, Lambrecht BN: Inhaled iloprost suppresses the cardinal features of asthma via inhibition of airway dendritic cell function. J Clin Invest. 2007 Feb;117(2):464-72. [PubMed:17273558]
  5. Tsai AL, Vijjeswarapu H, Wu KK: Interaction between platelet receptor and iloprost isomers. Biochim Biophys Acta. 1988 Jul 21;942(2):220-6. [PubMed:2456096]
  6. Olschewski H, Rose F, Schermuly R, Ghofrani HA, Enke B, Olschewski A, Seeger W: Prostacyclin and its analogues in the treatment of pulmonary hypertension. Pharmacol Ther. 2004 May;102(2):139-53. [PubMed:15163595]
  7. Anderson JR, Nawarskas JJ: Pharmacotherapeutic management of pulmonary arterial hypertension. Cardiol Rev. 2010 May-Jun;18(3):148-62. doi: 10.1097/CRD.0b013e3181d4e921. [PubMed:20395700]
  8. Mubarak KK: A review of prostaglandin analogs in the management of patients with pulmonary arterial hypertension. Respir Med. 2010 Jan;104(1):9-21. doi: 10.1016/j.rmed.2009.07.015. Epub 2009 Aug 15. [PubMed:19683911]
  9. Krug S, Sablotzki A, Hammerschmidt S, Wirtz H, Seyfarth HJ: Inhaled iloprost for the control of pulmonary hypertension. Vasc Health Risk Manag. 2009;5(1):465-74. [PubMed:19475782]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Prostaglandin e receptor activity
Specific Function
Receptor for prostaglandin E2 (PGE2). The activity of this receptor is mediated by G(q) proteins which activate a phosphatidylinositol-calcium second messenger system. May play a role as an importa...
Gene Name
PTGER1
Uniprot ID
P34995
Uniprot Name
Prostaglandin E2 receptor EP1 subtype
Molecular Weight
41800.655 Da
References
  1. Sharif NA, Davis TL: Cloned human EP1 prostanoid receptor pharmacology characterized using radioligand binding techniques. J Pharm Pharmacol. 2002 Apr;54(4):539-47. [PubMed:11999132]
  2. Walch L, de Montpreville V, Brink C, Norel X: Prostanoid EP(1)- and TP-receptors involved in the contraction of human pulmonary veins. Br J Pharmacol. 2001 Dec;134(8):1671-8. [PubMed:11739243]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4A
Uniprot ID
P27815
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4A
Molecular Weight
98142.155 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging f...
Gene Name
PDE4B
Uniprot ID
Q07343
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Molecular Weight
83342.695 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Metal ion binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4C
Uniprot ID
Q08493
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4C
Molecular Weight
79900.795 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Ubiquitin protein ligase binding
Specific Function
Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
Gene Name
PDE4D
Uniprot ID
Q08499
Uniprot Name
cAMP-specific 3',5'-cyclic phosphodiesterase 4D
Molecular Weight
91114.1 Da
References
  1. Wilkens H, Guth A, Konig J, Forestier N, Cremers B, Hennen B, Bohm M, Sybrecht GW: Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation. 2001 Sep 11;104(11):1218-22. [PubMed:11551870]
  2. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Weissmann N, Schudt C, Tenor H, Seeger W, Grimminger F: Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension. Crit Care Med. 2002 Nov;30(11):2489-92. [PubMed:12441759]
  3. Schermuly RT, Leuchte H, Ghofrani HA, Weissmann N, Rose F, Kohstall M, Olschewski H, Schudt C, Grimminger F, Seeger W, Walmrath D: Zardaverine and aerosolised iloprost in a model of acute respiratory failure. Eur Respir J. 2003 Aug;22(2):342-7. [PubMed:12952271]
  4. Grant PG, Mannarino AF, Colman RW: cAMP-mediated phosphorylation of the low-Km cAMP phosphodiesterase markedly stimulates its catalytic activity. Proc Natl Acad Sci U S A. 1988 Dec;85(23):9071-5. [PubMed:2461561]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Other/unknown
General Function
Serine-type endopeptidase activity
Specific Function
Converts the abundant, but inactive, zymogen plasminogen to plasmin by hydrolyzing a single Arg-Val bond in plasminogen. By controlling plasmin-mediated proteolysis, it plays an important role in t...
Gene Name
PLAT
Uniprot ID
P00750
Uniprot Name
Tissue-type plasminogen activator
Molecular Weight
62916.495 Da
References
  1. Kerins DM, Roy L, Kunitada S, Adedoyin A, FitzGerald GA, Fitzgerald DJ: Pharmacokinetics of tissue-type plasminogen activator during acute myocardial infarction in men. Effect of a prostacyclin analogue. Circulation. 1992 Feb;85(2):526-32. [PubMed:1370924]
  2. Nicolini FA, Mehta JL, Nichols WW, Saldeen TG, Grant M: Prostacyclin analogue iloprost decreases thrombolytic potential of tissue-type plasminogen activator in canine coronary thrombosis. Circulation. 1990 Mar;81(3):1115-22. [PubMed:1689620]
  3. Nichols WW, Nicolini FA, Saldeen TG, Mehta JL: Combined thrombolytic effects of tissue-plasminogen activator and a fibrinogen-degradation product peptide 6A or iloprost. J Cardiovasc Pharmacol. 1991 Aug;18(2):231-6. [PubMed:1717784]
  4. Nizankowski R, Krzanowski M, Musial J, Szczeklik A: [Effect of thromboxane A2 synthetase inhibitor and prostacyclin analogue on arterial blood pressure, fibrinolysis and platelet function in patients with hypertension]. Pol Tyg Lek. 1991 Jan 7-14;46(1-3):18-21. [PubMed:1726988]
  5. Herczenik E, Bouma B, Korporaal SJ, Strangi R, Zeng Q, Gros P, Van Eck M, Van Berkel TJ, Gebbink MF, Akkerman JW: Activation of human platelets by misfolded proteins. Arterioscler Thromb Vasc Biol. 2007 Jul;27(7):1657-65. Epub 2007 May 17. [PubMed:17510465]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Prostaglandin j receptor activity
Specific Function
Receptor for prostaglandin D2 (PGD2). Coupled to the G(i)-protein. Receptor activation may result in pertussis toxin-sensitive decreases in cAMP levels and Ca(2+) mobilization. PI3K signaling is al...
Gene Name
PTGDR2
Uniprot ID
Q9Y5Y4
Uniprot Name
Prostaglandin D2 receptor 2
Molecular Weight
43267.15 Da
References
  1. Wright DH, Metters KM, Abramovitz M, Ford-Hutchinson AW: Characterization of the recombinant human prostanoid DP receptor and identification of L-644,698, a novel selective DP agonist. Br J Pharmacol. 1998 Apr;123(7):1317-24. [PubMed:9579725]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as taurocholate, the prostaglandins PGD2, PGE1, PGE2, leukotriene C4, thromboxane B2 and iloprost.
Gene Name
SLCO2B1
Uniprot ID
O94956
Uniprot Name
Solute carrier organic anion transporter family member 2B1
Molecular Weight
76709.98 Da
References
  1. Nishio T, Adachi H, Nakagomi R, Tokui T, Sato E, Tanemoto M, Fujiwara K, Okabe M, Onogawa T, Suzuki T, Nakai D, Shiiba K, Suzuki M, Ohtani H, Kondo Y, Unno M, Ito S, Iinuma K, Nunoki K, Matsuno S, Abe T: Molecular identification of a rat novel organic anion transporter moat1, which transports prostaglandin D(2), leukotriene C(4), and taurocholate. Biochem Biophys Res Commun. 2000 Sep 7;275(3):831-8. [PubMed:10973807]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
May mediate the release of newly synthesized prostaglandins from cells, the transepithelial transport of prostaglandins, and the clearance of prostaglandins from the circulation. Transports PGD2, a...
Gene Name
SLCO2A1
Uniprot ID
Q92959
Uniprot Name
Solute carrier organic anion transporter family member 2A1
Molecular Weight
70043.33 Da
References
  1. Lu R, Kanai N, Bao Y, Schuster VL: Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. [PubMed:8787677]
  2. Kanai N, Lu R, Satriano JA, Bao Y, Wolkoff AW, Schuster VL: Identification and characterization of a prostaglandin transporter. Science. 1995 May 12;268(5212):866-9. [PubMed:7754369]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Sodium-independent organic anion transmembrane transporter activity
Specific Function
Mediates the Na(+)-independent transport of organic anions such as estrone-3-sulfate (PubMed:10873595). Mediates transport of prostaglandins (PG) E1 and E2, thyroxine (T4), deltorphin II, BQ-123 an...
Gene Name
SLCO3A1
Uniprot ID
Q9UIG8
Uniprot Name
Solute carrier organic anion transporter family member 3A1
Molecular Weight
76552.135 Da
References
  1. Adachi H, Suzuki T, Abe M, Asano N, Mizutamari H, Tanemoto M, Nishio T, Onogawa T, Toyohara T, Kasai S, Satoh F, Suzuki M, Tokui T, Unno M, Shimosegawa T, Matsuno S, Ito S, Abe T: Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. [PubMed:14631946]

Drug created on June 13, 2005 07:24 / Updated on December 01, 2017 14:38